The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer’s dementia.
The PI of this project is: Cynthia Carlsson, MD
This project is funded by: Janssen Pharmaceutical
The term of this project is: April 2018 to September 2023
The number of subjects scanned during this project is: 30